WO1991003248A3 - Procede d'activation du systeme immunitaire - Google Patents

Procede d'activation du systeme immunitaire

Info

Publication number
WO1991003248A3
WO1991003248A3 PCT/US1990/005022 US9005022W WO9103248A3 WO 1991003248 A3 WO1991003248 A3 WO 1991003248A3 US 9005022 W US9005022 W US 9005022W WO 9103248 A3 WO9103248 A3 WO 9103248A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune system
system activation
chemotherapy
treatment
surgery
Prior art date
Application number
PCT/US1990/005022
Other languages
English (en)
Other versions
WO1991003248A2 (fr
Inventor
Spiros Jamas
D Davidson Easson Jr
Gary R Ostroff
Original Assignee
Alpha Beta Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Technology filed Critical Alpha Beta Technology
Priority to EP90914341A priority Critical patent/EP0491829B1/fr
Priority to AU64292/90A priority patent/AU647751B2/en
Priority to DE69030880T priority patent/DE69030880T2/de
Publication of WO1991003248A2 publication Critical patent/WO1991003248A2/fr
Publication of WO1991003248A3 publication Critical patent/WO1991003248A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
  • Massaging Devices (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
PCT/US1990/005022 1989-09-08 1990-09-05 Procede d'activation du systeme immunitaire WO1991003248A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP90914341A EP0491829B1 (fr) 1989-09-08 1990-09-05 Compositon activant le systeme immunaire
AU64292/90A AU647751B2 (en) 1989-09-08 1990-09-05 Method for immune system activation
DE69030880T DE69030880T2 (de) 1989-09-08 1990-09-05 Zusammensetzung zur Stimulierung des Immunsystems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40476589A 1989-09-08 1989-09-08
US404,765 1989-09-08

Publications (2)

Publication Number Publication Date
WO1991003248A2 WO1991003248A2 (fr) 1991-03-21
WO1991003248A3 true WO1991003248A3 (fr) 1991-06-13

Family

ID=23600941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/005022 WO1991003248A2 (fr) 1989-09-08 1990-09-05 Procede d'activation du systeme immunitaire

Country Status (9)

Country Link
US (1) US5504079A (fr)
EP (1) EP0491829B1 (fr)
JP (1) JPH05502018A (fr)
AT (1) ATE153856T1 (fr)
AU (1) AU647751B2 (fr)
CA (1) CA2067159A1 (fr)
DE (1) DE69030880T2 (fr)
ES (1) ES2103276T3 (fr)
WO (1) WO1991003248A2 (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
EP0640348A1 (fr) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Mélange adjuvant à base d'huile et à base d'eau
ATE196609T1 (de) * 1993-07-28 2000-10-15 Diatide Inc Radiomarkierte glukane
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
GB2325233B (en) * 1997-05-16 2001-07-18 Norsk Hydro As Substrates having bound polysaccharides and bacterial nucleic acids
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
AU6261999A (en) 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6369216B1 (en) 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20020123129A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for degrading nitrogen-containing compounds
US20020123130A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for degrading polymeric compounds
US20020123127A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for reducing odor
US6939864B1 (en) 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
NO20014256D0 (no) * 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US20040248772A1 (en) * 2001-11-06 2004-12-09 Akikuni Yagita Anticancer compositions
US7256026B2 (en) * 2002-06-28 2007-08-14 Ultra Biotech Limited Oral compositions for white blood cell activation and proliferation
US20040001857A1 (en) * 2002-06-28 2004-01-01 Cheung Ling Yuk Dietary supplements for treating hypertension
US20040005336A1 (en) * 2002-06-28 2004-01-08 Cheung Ling Yuk Dietary supplements for regulating the central nervous system
US20040001859A1 (en) * 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
US20040005335A1 (en) * 2002-06-28 2004-01-08 Cheung Ling Yuk Oral compositions for HIV-infected subjects
US20070042930A1 (en) * 2002-08-13 2007-02-22 Ross Gordon D Effect of beta-glucan on stem cell recruitment and tissue repair
WO2004014320A2 (fr) * 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Procedes d'utilisation du beta-glucane comme agent radioprotecteur
CA2496508C (fr) 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Therapie anticancereuse dans laquelle il est fait appel a du beta glucane et a des anticorps
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
EP1594418A2 (fr) * 2003-01-29 2005-11-16 Immudyne, Inc. Immunostimulant pour animaux
US7226600B2 (en) * 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7220416B2 (en) * 2003-06-11 2007-05-22 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223403B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204988B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223400B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7214377B2 (en) * 2003-06-11 2007-05-08 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204986B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6987012B2 (en) * 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US7204987B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Biological compositions and methods for treatment of prostate cancer
US6989253B2 (en) * 2003-06-11 2006-01-24 Ultra Biotech Limited Biological compositions and methods for treatment of testicular cancer
US7208158B2 (en) 2003-06-11 2007-04-24 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7201906B2 (en) * 2003-06-11 2007-04-10 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223405B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepareompositions comprising yeast treated with electromagnetic energy
US6984507B2 (en) * 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US7223404B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223401B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223402B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6984508B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US20040265990A1 (en) * 2003-06-30 2004-12-30 Cheung Ling Yuk Biological compositions for reduction of E. coli infections
EP1684777A2 (fr) * 2003-08-13 2006-08-02 University Of Louisville Research Foundation, Inc. Effet du glucan beta sur le recrutement de cellule souche et la regeneration des tissus
US6979562B2 (en) * 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US6964864B2 (en) * 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US7259001B2 (en) * 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US7297522B2 (en) * 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy
US20050106166A1 (en) * 2003-11-18 2005-05-19 Cheung Ling Y. Methods and compositions for treating liver cirrhosis
US20050106705A1 (en) * 2003-11-18 2005-05-19 Cheung Ling Y. Methods and compositions for treating hyperlipemia
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US7078202B2 (en) * 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US7197521B2 (en) * 2003-11-21 2007-03-27 Intel Corporation Method and system performing concurrently mark-sweep garbage collection invoking garbage collection thread to track and mark live objects in heap block using bit vector
US20050271613A1 (en) * 2004-03-29 2005-12-08 Toshio Suzuki Beta-1, 3-1, 6-D-glucan and its use
WO2006085895A2 (fr) * 2004-05-10 2006-08-17 Biopolymer Engineering, Inc. Particules de glucane entieres en combinaison avec des antibiotiques, des vaccins et des anticorps monoclonaux viraux
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US7514085B2 (en) 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
CN101052383B (zh) 2004-09-17 2013-01-30 马萨诸塞大学 用于溶酶体酶缺乏症的组合物和其用途
WO2006121803A1 (fr) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production de bêta-glucanes et de mannanes
EP1896600A2 (fr) 2005-06-15 2008-03-12 Medimush A/S Polythérapie contre le cancer et kit de composants associé
WO2006133708A1 (fr) * 2005-06-15 2006-12-21 Medimush A/S Agents bio-actifs produits par culture immergee de cellule de basidiomycete
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
US20090209624A1 (en) * 2005-10-24 2009-08-20 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007146440A2 (fr) * 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Préparations de glycane
US20080063650A1 (en) * 2006-09-01 2008-03-13 Jun Yan mCRP antagonists and their uses
WO2008027580A2 (fr) * 2006-09-01 2008-03-06 University Of Louisville COMPOSITIONS DE b-GLUCANE PARTICULAIRE POUR RÉGULER LES CELLULES DENDRITIQUES
WO2008057501A2 (fr) * 2006-11-06 2008-05-15 Whitehead Institute Compositions immunomodulatrices et leurs procédés d'utilisation
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
KR20090009513A (ko) * 2007-07-20 2009-01-23 한국원자력연구원 방사선 조사에 의한 저 분자량의 베타글루칸의 제조 방법및 방사선 조사에 의하여 제조된 저 분자량의 베타글루칸
WO2009042230A1 (fr) * 2007-09-27 2009-04-02 Biopolymer Engineering, Inc. Dba Biothera, Inc Traitement à base de β-glucane des symptômes d'une infection des voies respiratoires supérieures et du bien-être psychologique
EP2222283A2 (fr) 2007-10-29 2010-09-01 University of Massachusetts Proteins de levure membranaire encapsulées de facon multilayer pour l'administration d'acides nucléiques (siadn)
WO2010008582A2 (fr) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Système permettant d'administrer un médicament aux cellules phagocytaires
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2011011617A1 (fr) 2009-07-22 2011-01-27 Biothera, Inc. Compositions thérapeutiques et procédés associés
US9340786B2 (en) 2010-03-24 2016-05-17 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
EP3578183B1 (fr) 2010-03-24 2021-09-08 Phio Pharmaceuticals Corp. Interférence d'arn dans des indications oculaires
US20110293784A1 (en) 2010-05-28 2011-12-01 Anja Wittke Milk-based nutritional compositions
US9242857B2 (en) 2010-08-14 2016-01-26 University Of Massachusetts Yeast cell wall particles for receptor-targeted nanoparticle delivery
WO2015085113A1 (fr) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Méthodes de traitement de cicatrisation à l'aide d'oligonucléotides chimiquement modifiés
CA2947270A1 (fr) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Procedes de traitement du cancer au moyen d'un acide nucleique deciblage de mdm2 ou mycn
US20170051290A1 (en) 2014-05-01 2017-02-23 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
JP6893594B2 (ja) 2014-07-10 2021-06-23 ハイバーセル，インク． 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
WO2016073763A2 (fr) 2014-11-06 2016-05-12 Biothera, Inc. Compositions et procédés de bêta-glucane qui affectent le micro-environnement de la tumeur
EP3234141A4 (fr) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Composés reversir tm
EP3319614B1 (fr) 2015-07-06 2020-12-23 Phio Pharmaceuticals Corp. Molécules d'acide nucléique ciblant la superoxyde dismutase 1 (sod1)
WO2017007825A1 (fr) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Procédés pour le traitement de troubles neurologiques à l'aide d'une petite molécule synergique et approche thérapeutique utilisant des acides nucléiques
CA3002744A1 (fr) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Composes d'acides nucleiques de taille reduite a auto-administration ciblant des longs arn non codants
WO2018156888A1 (fr) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Immunopharmacodynamie de bêta-glucane
KR20200072886A (ko) 2018-12-13 2020-06-23 주식회사 글루칸 흑효모 유래 바이오폴리머 생산을 위한 배지 조성물 및 그를 이용한 흑효모 유래 바이오폴리머의 제조방법
WO2021064088A1 (fr) * 2019-10-04 2021-04-08 Universiteit Gent Bêta-glucanes ayant des propriétés d'immunostimulation supérieures
US20230002766A1 (en) 2019-11-08 2023-01-05 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
WO2024168010A2 (fr) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Molécules de reversir et leurs procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5571701A (en) * 1978-11-24 1980-05-30 Sankyo Co Ltd Hydrolyzate polysaccharide, its preparation, and immunoregulator containing hydrolyzate polysaccharide as active ingredient
JPS5676401A (en) * 1979-11-27 1981-06-24 Hitoshi Ito Simple glucan separated from cultured choray, preparation thereof and antitumor agent containing its polysaccharide as effective component
FR2477416A1 (fr) * 1980-03-10 1981-09-11 Unicler Utilisation de hansenula ou d'extraits de hansenula, comme medicament
JPS5945301A (ja) * 1982-09-09 1984-03-14 Toyo Soda Mfg Co Ltd 多糖類及びその製造法
JPS59210901A (ja) * 1983-05-17 1984-11-29 Nippon Kinoko Kenkyusho プロテオグルカン及びそれからなる抗ガン剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Patent Abstracts of Japan, vol. 4, no. 113 (C-021), 13 August 1980; & JP-A-55 071 701 (SANKYO CO. LTD) 30 May 1980 *
Patent Abstracts of Japan, vol. 5, no. 144 (C-071), 11 September 1981; & JP-A-56 076 401 (ITO HITOSHI et al.) 24 June 1981 *
Patent Abstracts of Japan, vol. 8, no. 134 (C-230), 21 June 1984; & JP-A-59 045 301 (TOKYO SODA KOGYO K.K.) 14 March 1984 *
Patent Abstracts of Japan, vol. 9, no. 78 (C-274), 6 April 1985; & JP-A-59 210 901 (NIHON KINOKO KENKYUSHO) 29 November 1984 *
Vestnik Federalniho Uradu Pro Vynalezy, no. 10, 13 October 1989, page 111 & CSD 809187 (L. MASLER et al.) *
Vestnik Federalniho Uradu Pro Vynalezy, no. 11, 14 November 1989, pages 122-123 & CS D 394486 (L. MASLER et al.) & CS 3945-86D (J. PASTYR et al.) *

Also Published As

Publication number Publication date
WO1991003248A2 (fr) 1991-03-21
DE69030880D1 (de) 1997-07-10
US5504079A (en) 1996-04-02
DE69030880T2 (de) 1997-09-18
AU647751B2 (en) 1994-03-31
ES2103276T3 (es) 1997-09-16
EP0491829A1 (fr) 1992-07-01
JPH05502018A (ja) 1993-04-15
EP0491829B1 (fr) 1997-06-04
AU6429290A (en) 1991-04-08
ATE153856T1 (de) 1997-06-15
CA2067159A1 (fr) 1991-03-09

Similar Documents

Publication Publication Date Title
WO1991003248A3 (fr) Procede d'activation du systeme immunitaire
WO2001012122A3 (fr) Procede et systeme de traitement de l'arret cardiaque par hypothermie
EP0911033A3 (fr) Procédés et médicaments pour le traitement de maladies par l'interferon à effets secondaires réduits
WO2001049236A3 (fr) Procédé et systeme de traitement de l'arrêt cardiaque
CA2204277A1 (fr) Vaccin polyvalent anti-meningite
PL287844A1 (en) Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases
EP1093816A3 (fr) Utilisation de la ST1435 dans la thérapie hormonale par voie transdermique
AU6006090A (en) A method of increasing adenosine excretion
PL326629A1 (en) Application of flupyrtin in prophylaxy and therapy of deseases associated with damaged hematopoietic cellular system
AU5643299A (en) Humic acid and its use in the treatment of various conditions
AU3401093A (en) Therapeutic agent for threatened abortion
CA2170142A1 (fr) Composition et methode pour stimuler le rendement de la reproduction
Mansi et al. Repeat administration of high dose melphalan in relapsed myeloma
EP0371733A3 (fr) Inhibiteurs de dopamine-bêta-hydroxylase
AU7373196A (en) Combination of temozolomide and alpha-ifn for the treatment of advanced cancer
MD1119G2 (ro) Metodă de tratament al afecţiunilor inflamatorii ale organelor genitale feminine
RU2068266C1 (ru) Способ повышения остроты слуха
CA2130988A1 (fr) Composition pharmaceutique pour le traitement d'une surdite soudaine
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
AU2396900A (en) Treatment and prevention of hiv and other viral infections
AU2450900A (en) Therapeutic nucleoside compound
MD1135F1 (en) Paradontium treatment method
GR1002969B (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε αιωρημα εμβρυικων κυτταρων με δραση ανοσοποιητικης υποκαταστασης και μεθοδος θεραπειας του συνδρομου της επικτητης μολυνσης ανοσοποιητικης ανεπαρκειας (hiv) με τη χρηση αυτου του παρασκευασματος.
MD197G2 (ro) Preparat şi procedeu de tratare a hipogalactiei
GR1002968B (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε εναιωρημα εμβρυικων κυτταρων με ανοσοδιορθωτικη δραση και μεθοδος θεραπειας ζαχαρωδους διαβητη με τη χρηση αυτου του παρασκευασματος.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: ABSTRACT AND DRAWING ADDED

WWE Wipo information: entry into national phase

Ref document number: 2067159

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990914341

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1990914341

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990914341

Country of ref document: EP